Investigation of the Efficacies of a Resveratrol Formula on Improvement of Skin Conditions and Inflammatory Related Factors

Skin Conditions Clinical Trial

— Resveratrol  

Official title:

Investigation of the Efficacies of a Resveratrol Formula on Improvement of Skin

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04456829
• Other study ID #: 20-0-54-B
• Status: Completed
• Phase: N/A
• Start date: September 17, 2020
• Est. completion date: December 31, 2020

Study information

• Verified date: January 2021
• Source: TCI Co., Ltd.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

To assess a resveratrol formula on improvement of skin conditions and inflammatory cytokines in blood

Recruitment information / eligibility

• Status: Completed
• Enrollment: 60
• Est. completion date: December 31, 2020
• Est. primary completion date: November 10, 2020
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 20 Years and older

Eligibility

Inclusion Criteria:

• Healthy volunteers aged above 20 years old

Exclusion Criteria:

• Subject who is not willing to participate in this study.

• Patients with diseases of the skin, heart, liver, kidney, endocrine and other organs and patients with mental illness (according to medical history).

• Subjects who have known cosmetic, drug or food allergies, difficulty in digestive tract absorption or disorder.

• Female who is pregnant or nursing or planning to become pregnant during the course of the study.

• Received facial laser therapy, chemical peeling or UV overexposure in the past 4 weeks.

• Subjects who have large spots (area >3 square centimeter) or abnormal acne.

Related Conditions & MeSH terms

• Disease
• Proinflammatory Cytokines
• Skin Conditions
• Skin Diseases

Intervention

Dietary Supplement:
• Resveratrol drink
Subjects will consume a bottle of resveratrol drink for two months.
• Placebo drink
Subjects will consume a bottle of placebo drink for two months.

Locations

Country	Name	City	State
Taiwan	Chia Nan University of Pharmacy & Science	Tainan City

Sponsors (1)

Lead Sponsor	Collaborator
TCI Co., Ltd.

Country where clinical trial is conducted

Taiwan, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The change of skin moisture	Corneometer® CM825 was utilized to measure skin moisture. Units: arbitrary Corneometer® units 0-120	0, 4, and 8 weeks
Primary	The change of skin elasticity	Cutometer® dual MPA 580 was utilized to measure skin elasticity (parameter R2). Units: µm penetration depth into the probe opening, expressed as curves	0, 4, and 8 weeks
Primary	The change of skin wrinkles	VISIA Complexion Analysis System was utilized to measure wrinkles. Units: arbitrary units	0, 4, and 8 weeks
Primary	The change of skin collagen density	DermaLab® USB - 20 MHz High Freq. Ultrasound probe was utilized to scan and analyze skin collagen density. Units: Intensity score	0, 4, and 8 weeks
Primary	The change of skin texture	VISIA Complexion Analysis System was utilized to measure skin texture. Units: arbitrary units	0, 4, and 8 weeks
Primary	The change of skin pores	VISIA Complexion Analysis System was utilized to measure skin pores. Units: arbitrary units	0, 4, and 8 weeks
Primary	The change of total antioxidant capacity of blood	Total Antioxidant Capacity Assay Kit	0 and 8 weeks
Primary	The change of TNF-alpha of blood	ELISA Kit	0 and 8 weeks
Primary	The change of IL-6 of blood	ELISA Kit	0 and 8 weeks
Primary	The change of IL-17 of blood	ELISA Kit	0 and 8 weeks
Primary	The change of IL-1ß of blood	ELISA Kit	0 and 8 weeks